Oxford Biomedica bags Novartis leukaemia deal

Pharmaceutical giant Novartis has signed up biotech firm Oxford Biomedica to provide its gene delivery technology for a programme targeting various forms of leukaemia.

Pharmaceutical giant Novartis has signed up biotech firm Oxford Biomedica to provide its gene delivery technology for a programme targeting various forms of leukaemia.

The deal, which is worth between £2.5m and £4.0m to Oxford Biomedica over the next 12 months, will see the Oxford company's LentiVector gene delivery technology manufacture clinical grade genetic material for Novartis's CTL019 clinical development programme.

CTL019 is the lead project in a leukaemia-focused collaboration between the Swiss 'big pharma' player and the University of Pennsylvania.

CTL019 uses a gene delivery system called a lentiviral vector to genetically modify a patient's immune cells before they are re-infused into patients.

According to Edison Investment Research, such 'ex vivo' techniques "are typically difficult to scale-up easily and the deal helps validate Oxford BioMedica's viral vector production expertise".

"Additionally, it also highlights that gene therapy has the potential to dramatically alter life-threatening and severely debilitating disease outcomes."

Oxford BioMedica's Chief Executive Officer John Dawson said: "The strategic investment in our specialist manufacturing capabilities is a pivotal step towards building a financially self-sustaining business and this collaboration is an example of how we can commercialise our expertise."

Edison notes that the Novartis payments should mean that the company, which had net cash at end-2012 of £14.1m and is estimated to be burning cash at around £1.0m per month, has enough cash to reach the second quarter of 2014.

Shares in Oxford Biomedica were up 15% at 1.9p by 09:49 on the morning of the announcement.

OH

Recommended

Three strong Asian stocks trading at bargain prices
Share tips

Three strong Asian stocks trading at bargain prices

Professional investor Nitin Bajaj of the Fidelity Asian Values investment trust picks three stocks that dominate their industries, earn good returns o…
20 Sep 2021
Why it pays to face up to your investment mistakes
Investment strategy

Why it pays to face up to your investment mistakes

Buying stocks can be a complicated business. But selling stocks can be tricky, too – even if you sell for the right reasons. Max King explains how to …
17 Sep 2021
Share tips of the week – 17 September
Share tips

Share tips of the week – 17 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Sep 2021
Royal Mail will deliver for investors – here's how to play it
Trading

Royal Mail will deliver for investors – here's how to play it

Royal Mail Group has found its feet in the past 18 months and looks cheap. Matthew Partridge looks at how to trade the shares.
14 Sep 2021

Most Popular

The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
How to stop recurring subscriptions becoming a drain on your money
Personal finance

How to stop recurring subscriptions becoming a drain on your money

Tracking and pruning subscriptions isn’t as easy as it sounds. Here's how to take charge.
14 Sep 2021